| Literature DB >> 32733280 |
Cong Lin1, Li-Jun Zhang2, Bo Li3, Feng Zhang4, Qing-Rong Shen3, Guo-Qing Kong3, Xiao-Fan Wang3, Shou-Hong Cui3, Rong Dai3, Wen-Qiang Cao5, Pu Zhang6.
Abstract
Hyperglycemia is the main feature of diabetes and may increase the risk of vascular calcification (VC), which is an independent predictor for cardiovascular and cerebrovascular diseases (CCD). Selenium (Se) may decrease the risk of CCD, and previous studies confirmed that Se-containing protein from Se-enriched Spirulina platensis (Se-SP) exhibited novel antioxidant potential. However, the effect of Se-SP against VC has been not investigated. Herein, the protective effect and underlying mechanism of Se-SP against high glucose-induced calcification in mouse aortic vascular smooth muscle cells (MOVAS) were explored. Inductively coupled plasma atomic emission spectroscopy (ICP-AES) results showed time-dependent uptake of Se-SP in MOVAS cells, which significantly inhibited high glucose-induced abnormal proliferation. Se-SP co-treatment also effectively attenuated high glucose-induced calcification of MOVAS cells, followed by decreased activity and expression of alkaline phosphatase (ALP). Further investigation revealed that Se-SP markedly prevented reactive oxygen species (ROS)-mediated DNA damage in glucose-treated MOVAS cells. ROS inhibition by glutathione (GSH) effectively inhibited high glucose-induced calcification, indicating that Se-SP could act as ROS inhibitor to inhibit high glucose-induced DNA damage and calcification. Moreover, Se-SP dramatically attenuated high glucose-induced dysfunction of mitogen-activated protein kinases (MAPKs) and phosphatidylinositol-3-kinase/AKT (PI3K/AKT) pathways. Se-SP after Se addition achieved enhanced potential in inhibiting high glucose-induced calcification, which validated that Se-SP as a new Se species could be a highly effective treatment for human CCD.Entities:
Keywords: ROS; Se-containing protein; Spirulina platensis; cardiovascular and cerebrovascular diseases; hyperglycemia; vascular calcification
Year: 2020 PMID: 32733280 PMCID: PMC7363841 DOI: 10.3389/fphys.2020.00791
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1Characterization and intracellular uptake of Se-SP. (A) Culture and morphology of Se-enriched S. platensis. Se-enriched S. platensis was cultured with Zarrouk medium (pH 9.0) in a 1000 ml Erlenmeyer flask (A1). Morphology of Se-enriched S. platensis was detected by Light microscope (A2) and fluorescence microscope (A3). (B) UV–VIS spectra of Se-SP. Se-SP crude was extracted from Se-enriched S. platensis by ultrasonication, and absorption spectra of Se-SP were detected by UV–VIS spectrophotometer. (C) Emission spectrum of Se-SP. Fluorescence spectrum of Se-SP was examined by fluorescence microreader. Dose-dependent (D) and time-dependent (E) cellular uptake of Se-PC. MOVAS cells were treated with 0.1–20 μg/ml Se-SP for 1–48 h, and the intracellular uptake of Se-SP was examined by ICP-AES method. All data were shown from three different experiments. Bars with “*” or “**” indicate a statistical level of P < 0.05 and P < 0.01, respectively. Bars with different letters suggest significance at the level of P < 0.05.
FIGURE 2Se-SP inhibits high glucose-induced proliferation of MOVAS cells. (A) Dose-dependent proliferation of high glucose-treated MOVAS cells. MOVAS cells were treated with 10–50 mM glucose for 48 h. Cells treated with medium containing 5 mM glucose was set as the control group. (B) Time-dependent proliferation of high glucose-treated MOVAS cells. MOVAS cells were treated with 25 mM glucose for 1–48 h. (C) Cytotoxicity of SP and Se-SP on MOVAS cells. MOVAS cells were treated with 5–20 μg/ml SP or Se-SP for 48 h. (D) Se-SP inhibited high glucose-induced cell proliferation. MOVAS cells were co-treated with 5–10 μg/ml Se-SP and 25 mM glucose for 48 h. Cell viability was detected by MTT assay. All data are shown from three different experiments. Bars with “*” or “**” indicate a statistical level of P < 0.05 and P < 0.01, respectively. Bars with different letters are statistical significance at P < 0.05 level.
FIGURE 3Se-SP attenuates high glucose-induced calcification of MOVAS cells. (A) Se-SP inhibited high glucose-induced calcification of MOVAS cells. MOVAS cells seeded in six-well plate were treated with 10 μg/ml Se-SP or/and 25 mM glucose for 14 days. Calcium nodules were stained by alizarin red and observed under light microscope. (B) Absorbance of alizarin red. Alizarin red dye in the parallel experiments was eluted with 10% formic acid and quantified by a microplate reader at 420 nm and expressed as the optical density units. (C) Determination of calcium content. Protein was quantified by BCA kit, and calcium level was measured by O-cresolphthalein complexone method. Calcium content was expressed as μg/mg protein. All data were shown from three different experiments. Bars with different letters are statistical significance at the level of P < 0.05.
FIGURE 4Se-SP suppresses high glucose-induced ALP activity and expression. (A) ALP staining of MOVAS cells. MOVAS cells seeded in six-well plate were co-treated with 10 μg/ml Se-SP or/and 25 mM glucose for 14 days. ALP staining was conducted by an ALP staining kit. (B) Determine of ALP activity of MOVAS cells. Total protein of cells was prepared and quantified by BCA kit. ALP activity was examined by an ALP activity kit according to the manufacturer’s instructions. (C) Time-dependent expression of ALP in glucose-treated MOVAS cells. MOVAS cells were treated with 25 mM glucose for 1–14 days. (D) Se-PC inhibits ALP expression in high glucose-treated cells. ALP expression was detected by western blot analysis.
FIGURE 5Se-SP prevents ROS-mediated DNA damage in glucose-treated MOVAS cells. (A) High glucose-induced time-dependent ROS generation. MOVAS cells seeded in six-well plate were treated with 25 mM glucose for 10–120 min. DCFH-DA probe was loaded and the ROS generation (green fluorescence) was imaged by a fluorescent microscope. (B) High glucose-induced time-dependent DNA damage. MOVAS cells seeded in 9-cm plate were exposed to 25 mM glucose for 1–14 days. (C) Se-PC prevents high glucose-induced DNA damage. MOVAS cells were treated with 10 μg/ml Se-SP or/and 25 mM glucose for 14 days. (D) Absorbance of alizarin red. Alizarin red dye in the parallel experiments was eluted with 10% formic acid and quantified by a microplate reader at 420 nm and expressed as the optical density units. (E) Determination of calcium content. MOVAS cells were pre-treated with 5 mM GSH for 2 h before glucose treatment. Protein was quantified by BCA kit, and calcium level was measured by O-cresolphthalein complexone method. Calcium content was expressed as μg/mg protein. Protein expression was examined by western blotting.
FIGURE 6Se-SP improves high glucose-induced dysfunction of MAPKs and PI3K/AKT pathways. (A) High glucose-induced time-dependent activation of MAPKs pathway. (B) High glucose-induced time-dependent inactivation of PI3K/AKT pathway. MOVAS cells seeded in 9-cm plate were treated with 25 mM glucose for 1–14 days. (C) Se-SP improves high glucose-induced dysfunction of MAPKs and PI3K/AKT pathways. Western blotting was used to examine protein expression. (D) SP600125 (JNK inhibitor) blocked high glucose-induced calcification of MOVAS cells. MOVAS cells were co-treated with 10 μM SP600125 and 25 mM glucose for 14 days. Calcium nodules were stained by alizarin red. (E) Measurement of calcium content. Bars with different letters are statistical significance at the level of P < 0.05.